AttendMe Owl Logo
AttendMe
Evidence Evolution
EndocrinologyEndocrinology

How This Evidence Evolved

Testosterone Replacement CV Safety

From safety concerns to definitive cardiovascular outcome data

7.5

Timeline

Signal

Early observations and pilot data that first suggested a new direction

The TOM trial studied testosterone gel in men aged at least 65 with low testosterone and mobility limitations. It stopped early on the data and safety monitoring board’s recommendation because cardiovascular adverse events were more frequent with testosterone. Among 209 men, mean age 74, 23 testosterone-treated subjects and five placebo-treated subjects had cardiovascular-related adverse events. The small trial and high prevalence of chronic disease limit broader inferences.
Proof

Landmark RCTs and pivotal trials that established the evidence base

The TRAVERSE trial, a multicenter, randomized, double-blind, placebo-controlled noninferiority trial, tested cardiovascular safety in a defined population. It randomized 5,246 men aged 45-80 with hypogonadism and preexisting or high risk of cardiovascular disease to daily transdermal 1.62% testosterone gel or placebo gel; mean treatment duration was 21.7 months and mean follow-up 33.0 months. The primary MACE endpoint occurred in 7.0% of the testosterone group versus 7.3% of placebo (HR 0.96; 95% CI 0.78-1.17; P<0.001 for noninferiority), confirming cardiovascular noninferiority. Atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone.
Extension

Follow-up studies, subgroup analyses, and real-world validation

Secondary analyses of TRAVERSE provided additional nuance. Atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone. In the prostate analysis (5204 men), high-grade prostate cancer occurred in 0.19% vs 0.12% (HR 1.62, 95% CI 0.39-6.77; P = .51), other prostate events did not differ significantly, and PSA rose more with testosterone. Earlier, the Testosterone Trials (790 men aged 65 or older, 1 year of gel) found increased sexual activity, desire and erectile function and slightly better mood, but no vitality benefit. Walking improvement was not significant within the Physical Function Trial but was significant across all three trials, providing the efficacy context alongside TRAVERSE safety data.
Guidelines

Integration into clinical practice guidelines and recommendations

The 2018 Endocrine Society guideline recommends testosterone for symptomatic deficiency with consistently low testosterone and monitoring of testosterone, hematocrit and prostate cancer risk during the first year. The European Expert Panel considers therapy cardiovascularly safe in selected, regularly monitored men. In TRAVERSE, testosterone was noninferior to placebo for major adverse cardiac events in men with hypogonadism and preexisting or high cardiovascular risk; atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent.
Endocrine Society
European Expert Panel
Now

Current standard of care and ongoing research directions

TRAVERSE established noninferiority to placebo for MACE in men aged 45–80 with hypogonadism and preexisting or high cardiovascular risk. It did not resolve every safety question: atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone. Mean treatment duration was 21.7 months and follow-up 33 months; these results do not establish safety across all formulations, populations or longer treatment periods.

Landmark Trials in This Story

TOM2010Landmark

Adverse events associated with testosterone administration

Subjects with cardiovascular-related adverse events: testosterone 23 vs placebo 5; stopped early by DSMB

New England journal of medicineRCTN=209
TRAVERSE2023Landmark

Cardiovascular Safety of Testosterone-Replacement Therapy

MACE (CV death, nonfatal MI, nonfatal stroke): HR 0.96 (95% CI 0.78-1.17; noninferiority confirmed)

New England journal of medicineRCTN=5,246
TTrials2016

Effects of Testosterone Treatment in Older Men.

Sexual activity (Psychosexual Daily Questionnaire) at 1 year: testosterone vs placebo, increased (P<0.001); 6-minute walk gain of 50 m or more in all trials: 20.5% vs 12.6% (P=0.003), not significant within the Physical Function Trial

N Engl J MedThree coordinated placebo-controlled trials (Sexual Function, Physical Function, Vitality); testosterone gel vs placebo gel for 1 year in men aged 65 or older with testosterone below 275 ng/dLN=790
TRAVERSE Prostate Safety2023

Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.

High-grade prostate cancer over 14,304 person-years: testosterone 5 of 2596 (0.19%) vs placebo 3 of 2602 (0.12%) (HR 1.62, 95% CI 0.39-6.77; P = .51)

JAMA Netw OpenProstate safety analysis of a placebo-controlled, double-blind RCT (TRAVERSE, NCT03518034) at 316 US sites; 5204 men analyzedN=5,246
Endocrine Society 2018 Guideline2018

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.

Recommends diagnosing hypogonadism only in men with symptoms and signs of testosterone deficiency and unequivocally and consistently low serum testosterone; testosterone therapy for symptomatic deficiency; monitoring of symptoms, adverse effects, serum testosterone, hematocrit and prostate cancer risk during the first year

J Clin Endocrinol MetabClinical practice guideline (Endocrine Society)
European Expert Panel Position Statement2026

Cardiovascular safety of testosterone therapy-Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research.

Consensus that testosterone therapy prescribed to appropriately selected patients and monitored regularly is safe from a cardiovascular standpoint; in agreement with recent US FDA label changes for testosterone products

AndrologyExpert panel position statement

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Is testosterone replacement therapy safe for the heart?+
TRAVERSE randomized 5246 men with hypogonadism and preexisting or high cardiovascular risk. Transdermal testosterone was noninferior to placebo for MACE (HR 0.96; 95% CI 0.78–1.17). Atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone; MACE noninferiority does not remove those signals.
What monitoring is needed during testosterone therapy?+
In TRAVERSE, atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026